Get started
Author

Petr Karásek

Observed names: Karásek, Petr, P Karasek, P Karásek, P. Karasek, P. Karásek, PETR KARASEK, Petr Karasek
Observed institutions: Brown University, The Alfred Hospital, Amsterdam UMC Location University of Amsterdam, Medizinische Hochschule Hannover, Masaryk Memorial Cancer Institute, The Christie Hospital, University Medical Centre Mannheim, Charité – Universitätsmedizin Berlin
ORCID: 0009-0008-1772-5709
Observed ORCID: 0009-0008-1772-5709
OpenAlex ID: A5090083240
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 · JY Douillard, D Cunningham, et al. · The Lancet · 3,288
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
2004 · E. Van Cutsem, H. van de Velde, et al. · Journal of Clinical Oncology · 797
Lipidomic profiling of human serum enables detection of pancreatic cancer
2022 · Denise Wolrab, Robert Jirásko, et al. · Nature Communications · 200
PDF
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
2013 · Philippe Rougier, Hanno Riess, et al. · European Journal of Cancer · 188
MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
2016 · Eric Van Cutsem, Heinz-Josef Lenz, et al. · Journal of Clinical Oncology · 75
MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
2015 · Petra Vychytilova-Faltejskova, Igor Kiss, et al. · Diagnostic Pathology · 73
PDF
Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection
2018 · PETR KARASEK, NATALIA GABLO, et al. · Cancer Genomics & Proteomics · 51
PDF
Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma
2016 · Jan Skoda, Marketa Hermanova, et al. · PLoS ONE · 49
PDF
G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study
2005 · J. Shapiro, J. Marshall, et al. · Journal of Clinical Oncology · 45
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.
2016 · Eric Van Cutsem, Heinz-Josef Lenz, et al. · Journal of Clinical Oncology · 34
Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
2011 · Jiri Lenz, Petr Karasek, et al. · PubMed · 28
Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma
2009 · Marketa Hermanova, Petr Karasek, et al. · Pancreas · 16
Anterior Gradient 2 and Mucin 4 Expression Mirrors Tumor Cell Differentiation in Pancreatic Adenocarcinomas, But Aberrant Anterior Gradient 2 Expression Predicts Worse Patient Outcome in Poorly Differentiated Tumors
2013 · Veronika Brychtova, Marketa Hermanova, et al. · Pancreas · 12
Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study
2003 · Petr Karasek, Tomas Skacel, et al. · Expert Opinion on Pharmacotherapy · 11
Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum
2026 · Ondřej Peterka, Robert Jirásko, et al. · Communications Medicine · 6
PDF
[Regional chemotherapy of liver tumors].
1997 · J Zaloudík, I Kocák, et al. · PubMed · 2
Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)
1999 · P. Rougier, D. Cunningham, et al. · European Journal of Cancer · 1
Current diagnostic and treatment options for pancreatic cancer in 2024.
2024 · Radim Němeček, Petr Karásek · PubMed
Prognostic and Predictive Factors for Pancreatic Adenocarcinoma
2016 · Petr Karásek, Markéta Hermanová · Klinicka onkologie
PDF
Chemoterapie jaterních metastáz : Český a slovenský gastroenterologický kongres, Brno, 9.-11.9.1999. Abstrakta. Multimodální terapie jaterních metastáz nádorů GIT
2015 · P. Karásek, Jan Žaloudík, et al. · Gastroenterologie a hepatologie
Irinotecan (IRI) v terapii pokročilého kolorektálního karcinomu (KRK). Výsledky u pacientů léčených v Masarykově onkologickém ústavu (MOU) za období roku 1997-1998 : Český a slovenský gastroenterologický kongres, Brno, 9.-11.9.1999. Abstrakta.
2015 · P. Karásek, Jaroslav Němec, et al. · Gastroenterologie a hepatologie
A Case Report: Patient with Metastatic Goblet Cell Carcinoid
2013 · Beatrix Bencsiková, Andrea Jurečková, et al. · Klinicka onkologie
PDF
Erlotinib v léčbě pokročilého karcinomu pankreatu
2013 · Petr Karásek, Beatrix Bencsiková, et al.
[Concomitant chemoradiotherapy in tumors of the pancreas].
2003 · R Soumarová, H Perková, et al. · PubMed
[Diagnosis and therapy of pancreatic tumors].
2002 · R Soumarová, H Perková, et al. · PubMed
Works count: 29
Citation count: 4,853
H-index: 12
I10-index: 14
Year
Topic
Type